Micro-X Raises $6M, Billion Prima Boosts Stake to 8.5% Amid Medical Imaging Push
Micro-X Limited has secured $6 million through a share placement to accelerate commercialisation of its innovative medical imaging technologies, with strategic partner Billion Prima increasing its stake to 8.5%. The capital raise supports key clinical trials and product development milestones.
- Placement raises $6 million at $0.08 per share
- Billion Prima commits $3 million, increasing holding to 8.5% and gains board seat
- Head CT enters hospital and ambulance imaging trials ahead of 2026 regulatory submissions
- US Department of Homeland Security contract worth up to $31.7 million advancing
- Strong sales momentum with record $3.3 million Rover order and US healthcare supply agreement
Capital Raising to Fuel Medical Imaging Commercialisation
Micro-X Limited (ASX – MX1) has announced a $6 million capital raising via a placement of approximately 75 million new shares priced at $0.08 each. The funds are earmarked to advance the commercialisation of its cutting-edge medical imaging products, including the Head CT and Full Body CT scanners. This capital injection is timely as the company moves into critical clinical trial phases and scales manufacturing capabilities.
Strategic Partner Billion Prima Increases Stake
Notably, strategic partner Billion Prima Sdn Bhd is committing an additional US$2 million (around A$3 million), boosting its shareholding from 4.0% to approximately 8.5%. This investment comes with the right to nominate a director to Micro-X’s board, reflecting Billion Prima’s growing influence and confidence in the company’s trajectory. Billion Prima’s involvement also extends to collaboration on security scanning technologies, which Micro-X plans to monetise to support its medical imaging focus.
Clinical Trials and Regulatory Milestones on the Horizon
Micro-X is progressing hospital-based human imaging trials for its Head CT scanner, funded by an $8 million grant from the Australian Stroke Alliance. These trials, set to commence in early 2026, are pivotal for regulatory submissions planned later that year. Complementing this, a $4.4 million non-dilutive grant supports ambulance trials, aiming to enable stroke diagnosis in pre-hospital settings. Meanwhile, the Full Body CT project has secured up to $25 million in funding from the US government’s ARPA-H agency, targeting portable CT solutions for rural and remote healthcare.
Robust Sales Momentum and Expanding Pipeline
Micro-X’s Rover mobile digital radiography system continues to gain traction, highlighted by a record $3.3 million order from Malaysian distributor Integrated Medical Systems for the Malaysian Ministry of Health. Additionally, a supply agreement with a major US healthcare group operating over 700 facilities signals growing adoption in key markets. The company is actively pursuing further large sales opportunities across the US and other regions, supported by product updates that improve manufacturing efficiency and margins.
Monetising Security Assets to Support Growth
While Micro-X is sharpening its focus on medical imaging, it maintains a significant contract with the US Department of Homeland Security valued at up to $31.7 million for developing advanced security imaging solutions. The company is in advanced negotiations to monetise these security technologies, aiming to unlock additional capital and streamline its business towards its core medical imaging ambitions.
Navigating Risks Amid Ambitious Growth Plans
Despite promising developments, Micro-X faces typical early-stage commercialisation risks, including regulatory hurdles, competitive pressures, and the need to secure ongoing funding. The company’s success hinges on achieving clinical trial milestones, converting sales opportunities, and executing strategic partnerships. Investors should weigh these factors alongside the company’s clear path to cash flow breakeven and expanding commercial footprint.
Bottom Line?
Micro-X’s $6 million raise and Billion Prima’s increased stake set the stage for a pivotal 2026 as the company advances clinical trials and commercial growth.
Questions in the middle?
- Will Micro-X successfully convert its growing sales pipeline into sustained revenue?
- How will regulatory approvals for the Head CT and Full Body CT scanners progress through 2026?
- What are the terms and timing of the anticipated monetisation of Micro-X’s security technology assets?
